INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Abbott Reports Second-Quarter Results
With results ahead of expectations, Abbott's is among top healthcare companies raising its outlook for 2018.
Abbott's second-quarter results are in, and we delivered another strong quarter in healthcare sector growth thanks to a strong product pipeline and outstanding execution by our management team.
For the quarter, Abbott beat Street estimates on the top and bottom line, delivering impressive organic sales and double-digit EPS growth. Today's results extend our decade-long streak of meeting or beating Street-adjusted EPS estimates every quarter.
And, with all four of our businesses — Diagnostics, Devices, Nutrition and Medicines — contributing to strong growth in the quarter, Abbott announced plans to raise its outlook for the rest of the year.
The strong healthcare sector growth we're achieving is a direct result of the strategic steps we've taken to position the company in the most attractive areas of healthcare and the productivity of our life-changing technologies.
What follows is just a few of our highlights from the quarter:
For full financials, you can read our press release, but major highlights are included in the materials below:
Abbott's Chairman and CEO Miles D. White shared his views on second-quarter performance:
Learn more about Abbott’s second-quarter 2018 results:
Download a summary of Abbott's earnings highlights here
For more information on Abbott's earnings results, see the news release.
* Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
Indications and Important Safety Information
The FreeStyle Libre Flash Glucose Monitoring system is a continuous glucose monitoring (CGM) device indicated for replacing blood glucose testing and detecting trends and tracking patterns aiding in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments in persons (age 18 and older) with diabetes. The system is intended for single patient use and requires a prescription.
CONTRAINDICATIONS:
Remove the sensor before MRI, CT scan, X-ray, or diathermy treatment.
WARNINGS/LIMITATIONS:
Do not ignore symptoms that may be due to low or high blood glucose, hypoglycemic unawareness, or dehydration. Check sensor glucose readings with a blood glucose meter when Check Blood Glucose symbol appears, when symptoms do not match system readings, or when readings are suspected to be inaccurate. The FreeStyle Libre system does not have alarms unless the sensor is scanned, and the system contains small parts that may be dangerous if swallowed. The FreeStyle Libre system is not approved for pregnant women, persons on dialysis, or critically-ill population. Sensor placement is not approved for sites other than the back of the arm and standard precautions for transmission of blood borne pathogens should be taken. The built-in blood glucose meter is not for use on dehydrated, hypotensive, in shock, hyperglycemic-hyperosmolar state, with or without ketosis, neonates, critically-ill patients, or for diagnosis or screening of diabetes. Review all product information before use or contact Abbott Toll Free (855-632-8658) or visit www.freestylelibre.us for detailed indications for use and safety information